本研究旨在证实白细胞介素-2(interleukin-2,IL-2)和淋巴因子激活的杀伤细胞(lymphokine-activated killer cells, LAKC)对转移性肾癌有抗瘤效应。研究采用非随机设计,系临床Ⅱ期试验。35例病人,男25例,女10例,年龄19～65岁,均经组织学证明患有转移或不能手术切除的肾细胞癌,普通疗法未能洽愈。治疗时病灶转移至肺21例,腹部20例,骨骼 The aim of this study was to demonstrate that anti-tumor effects of interleukin-2 (IL-2) and lymphokine-activated killer cells (LAKC) on metastatic renal cancer. The study used a non-random design and was a clinical phase II trial. Thirty-five patients, 25 males and 10 females, aged 19 to 65 years, were histologically proven to have metastatic or inoperable renal cell carcinoma, and general therapy failed to resolve. At the time of treatment, lesions were transferred to lungs in 21 cases, abdominals in 20 cases, and bones.